$SDGR

Schrodinger, Inc. (SDGR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sdgr-20260630x8kxexx991.htm EX-99.1 Document Exhibit 99.1 Schrödinger Reports Second Quarter 2026 Financial Results Second Quarter ACV of $30 Million, Representing 27% Growth Launched Early Access Version of Bunsen, A New Agentic AI Co-Scientist for Molecular Discovery

Schrodinger, Inc. (SDGR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. sdgr-20260622 1540 Broadway 24th Floor New York NY FALSE 0001490978 0001490978 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 8-K ________________________________________ CURRENT REPORT P

Schrodinger, Inc. (SDGR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 exhibit101-mannixaklianxse.htm EX-10.1 Document Exhibit 10.1 TRANSITION, SEPARATION, AND RELEASE OF CLAIMS AGREEMENT This Transition, Separation, and Release of Claims Agreement (the “ Agreement ”) is entered into by and between Schrödinger, Inc. (the “ Company ”) and M

The article compares Recursion Pharmaceuticals (RXRX) and Schrödinger (SDGR) as digital drug-discovery platforms. Recursion reported FY2025 revenue of about $74.7M (+26.9%) and a net loss of about $644.8M, with negative free cash flow of about $378.3M and a debt-to-equity ratio near 0.1x. Schrödinger posted FY2025 revenue of about $255.9M (+23.3%), net loss about $103.3M, and free cash flow about $12.5M.

Tudor Investment Corp ET AL significantly increased its stake in Schrodinger, Inc. (NASDAQ:SDGR) by 2,530.6% during the third quarter, now owning 336,379 shares valued at approximately $6.75 million. Despite beating quarterly earnings and revenue expectations, Schrodinger remains unprofitable with negative margins, holding an average analyst rating of "Hold" and a price target of $21.13. Recent insider selling has occurred, but institutional investors hold a substantial 79.05% of the stock.

Schrödinger, Inc. (Nasdaq: SDGR) announced its participation in three investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference, Leerink Global Healthcare Conference 2026, and KBCM Healthcare Forum. Management will hold fireside chats at each event, accessible live and archived on Schrödinger’s investor relations website. The company pioneers molecular discovery with its computational platform for drug development and materials design.

Nikko Asset Management Americas Inc. increased its stake in Schrodinger, Inc. (NASDAQ:SDGR) by 7.2% in the second quarter, owning over 2.59 million shares worth $52.09 million. Other institutional investors like Rubric Capital Management LP and UBS AM also significantly boosted their holdings. The article also notes recent analyst rating changes and an insider stock sale by Margaret Dugan.

Schrodinger (SDGR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Schrodinger (SDGR) delivered earnings and revenue surprises of +40.00% and +8.68%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

The average of price targets set by Wall Street analysts indicates a potential upside of 40.4% in Schrodinger (SDGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.